Hyaluronan as drug carrier. The in vitro efficacy and selectivity of Hyaluronan–Doxorubicin complexes to affect the viability of overexpressing CD44 receptor cells

Battistini, F. D.; Flores-Martín, Jésica; Olivera, Marı́a Eugenia; Genti-Raimondi, Susana; Manzo, Rubén H.

doi:10.1016/j.ejps.2014.09.008

Cited by 18 publications

(15 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HA (molecular weight [MW] 500 kDa) was used as a targeting molecule and the HPNs were prepared using a high-pressure homogenization method with a microfluidizer (Danhier et al ., 2009; Zhan et al ., 2010; Zhao et al ., 2010; Battistini et al ., 2014). The HA was complexed onto the surface of the PNs using chelating covalent bonding attraction (Mercê et al ., 2002).…”

Section: Methodsmentioning

confidence: 99%

“…Some targeting molecules such as hyaluronic acid (HA), folic acid, L-biotin, lipoproteins, and cholesterol have been investigated for active delivery of PTX to tumor tissues (Danhier et al ., 2009; Zhan et al ., 2010; Zhao et al ., 2010; Battistini et al ., 2014). Among them, HA is preferentially studied because it is composed of a negatively charged polysaccha-ride with repeating glucuronic acid (GlcUA) and N-acetyl-D-glucosamine (GlcNAc) units.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Improved Antitumor Efficacy of Hyaluronic Acid-Complexed Paclitaxel Nanoemulsions in Treating Non-Small Cell Lung Cancer

Kim

Park

2017

Biomolecules & Therapeutics

View full text Add to dashboard Cite

Paclitaxel (PTX) is a effectively chemotherapeutic agent which is extensively able to treat the non-small cell lung, pancreatic, breast and other cancers. But it is a practically insoluble drug with water solubility less than 1 μg/mL, which restricts its therapeutic application. To overcome the problem, hyaluronic acid-complexed paclitaxel nanoemulsions (HPNs) were prepared by ionic complexation of paclitaxel (PTX) nanoemulsions and hyaluronic acid (HA) to specifically target non-small cell lung cancer. HPNs were composed of dl-α-tocopheryl acetate, soybean oil, polysorbate 80, ferric chloride, and HA and fabricated by high-pressure homogenization. The HPNs were 85.2 ± 7.55 nm in diameter and had a zeta potential of −35.7 ± 0.25 mV. The encapsulation efficiency was almost 100%, and the PTX content was 3.0 mg/mL. We assessed the in vivo antitumor efficacy of the HPNs by measuring changes in tumor volume and body weight in nude mice transplanted with CD44-overexpressing NCI-H460 xenografts and treated with a bolus dose of saline, Taxol®, PTX nanoemulsions (PNs), or HPNs at a dose of 25 mg/kg. Suppression of cancer cell growth was higher in the PN- and HPN-treated groups than in the Taxol® group. In particular, HPN treatment dramatically inhibited tumor growth, likely because of the specific tumor-targeting affinity of HA for CD44-overexpressed cancer cells. The loss of body weight and organ weight did not vary significantly between the groups. It is suggest that HPNs should be used to effective nanocarrier system for targeting delivery of non-small cell lung cancer overexpressing CD44 and high solubilization of poorly soluble drug.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Improved Antitumor Efficacy of Hyaluronic Acid-Complexed Paclitaxel Nanoemulsions in Treating Non-Small Cell Lung Cancer

Kim

Park

2017

Biomolecules & Therapeutics

View full text Add to dashboard Cite

show abstract

“…13 To enable drug delivery via active targeting of tumor receptors, various targeting molecules are used to deliver PTX to the cancer cells, including hyaluronan/hyaluronic acid (HA), L-biotin, folic acid, lipoprotein, and cholesterol. 4,9,[13][14][15][16][17][18][19] Among these, HA is widely investigated because of its unique properties. Cluster of differentiation 44 (CD44) is a cell surface glycoprotein that is not expressed in normal cells and is overexpressed in tumors; therefore, it can function as a tumor marker.…”

Section: Introductionmentioning

confidence: 99%

“…The CD44-HA ligand-receptor pair is well known for its active tumor-targeting efficacy in cancer therapy. 14,[20][21][22][23] The targeting delivery systems such as nanoparticles, polymeric micelles, liposomes, emulsions, and nanogels with HA provide several advantages as drug carriers in both active and passive targeting of tumor receptors for drug delivery. 8,10,24,25 However, there are still several limitations, including low tumor-targeting efficacy, low bioavailability, undesirable tissue distribution, low drug loading dose, the need for relatively large injection volumes, low antitumor efficacy, unpredictable toxicity, and an initial drug release burst.…”

Section: Introductionmentioning

confidence: 99%

Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer

Kim¹,

Park²

2017

IJN

View full text Add to dashboard Cite

“…The proportions of the D , DH + , and [

R^{-} D H^{+}

] species in the DNA–D x dispersions were determined by dialysis equilibrium using a tube of cellulose acetate membrane (12,000 Da; Sigma), according to a procedure described by Battistini et al [31]. Exactly 10 mL of DNA–D x aqueous dispersions were put into the dialysis tube (donor compartment ( d )), which was inserted in a stoppered flask (receptor compartment ( r )) containing 100 mL (V d /V r : 1/10) or 400 mL (V d /V r : 1/40) of water for 24 h at 25 °C under magnetic stirring at 32 rpm.…”

Section: Methodsmentioning

confidence: 99%

Interaction between DNA and Drugs Having Protonable Basic Groups: Characterization through Affinity Constants, Drug Release Kinetics, and Conformational Changes

2017

View full text Add to dashboard Cite

This paper reports the in vitro characterization of the interaction between the phosphate groups of DNA and the protonated species of drugs with basic groups through the determination of the affinity constants, the reversibility of the interaction, and the effect on the secondary structure of the macromolecule. Affinity constants of the counterionic condensation DNA–drug were in the order of 106. The negative electrokinetic potential of DNA decreased with the increase of the proportion of loading drugs. The drugs were slowly released from the DNA–drug complexes and had release kinetics consistent with the high degree of counterionic condensation. The circular dichroism profile of DNA was not modified by complexation with atenolol, lidocaine, or timolol, but was significantly altered by the more lipophilic drugs benzydamine and propranolol, revealing modifications in the secondary structure of the DNA. The in vitro characterization of such interactions provides a physicochemical basis that would contribute to identify the effects of this kind of drugs in cellular cultures, as well as side effects observed under their clinical use. Moreover, this methodology could also be projected to the fields of intracellular DNA transfection and the use of DNA as a carrier of active drugs.

show abstract

Hyaluronan as drug carrier. The in vitro efficacy and selectivity of Hyaluronan–Doxorubicin complexes to affect the viability of overexpressing CD44 receptor cells

Cited by 18 publications

References 34 publications

Improved Antitumor Efficacy of Hyaluronic Acid-Complexed Paclitaxel Nanoemulsions in Treating Non-Small Cell Lung Cancer

Improved Antitumor Efficacy of Hyaluronic Acid-Complexed Paclitaxel Nanoemulsions in Treating Non-Small Cell Lung Cancer

Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer

Interaction between DNA and Drugs Having Protonable Basic Groups: Characterization through Affinity Constants, Drug Release Kinetics, and Conformational Changes

Contact Info

Product

Resources

About